Quick Answer
Hepion Pharmaceuticals, Inc. reported Net Income Loss of -$8.28 million for the year ending 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +37.3% in Net Income Loss from 2024 to 2025.
- This data is from Hepion Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$168.2 thousand | Q1 2014: -$9.31 million | Q3 2014: -$1.47 million | Q4 2014: -$3.10 million | Q1 2015: -$4.40 million | Q3 2015: -$4.84 million | Q4 2015: -$3.03 million | Q1 2016: -$3.92 million | Q3 2016: -$4.82 million | Q4 2016: -$4.51 million | Q1 2017: -$7.62 million | Q2 2017: $2.05 million | Q3 2017: -$5.77 million | Q1 2018: -$2.69 million | Q2 2018: -$4.03 million | Q3 2018: -$157.1 thousand | Q1 2019: -$1.98 million | Q2 2019: -$1.02 million | Q3 2019: -$1.82 million | Q1 2020: -$4.23 million | Q2 2020: -$4.94 million | Q3 2020: -$6.23 million | Q1 2021: -$6.06 million | Q2 2021: -$7.67 million | Q3 2021: -$9.27 million | Q1 2022: -$6.93 million | Q2 2022: -$19.91 million | Q3 2022: -$8.55 million | Q1 2023: -$13.26 million | Q2 2023: -$14.08 million | Q3 2023: -$10.53 million | Q1 2024: -$2.85 million | Q2 2024: -$3.93 million | Q3 2024: -$4.87 million | Q1 2025: -$6.11 million | Q2 2025: -$1.04 million | Q3 2025: -$472.5 thousand.
- Over the full 12 years of available data (2014 to 2025), Hepion Pharmaceuticals, Inc.'s Net Income Loss has declined by 56.8%.
- Historical annual values: Fiscal year 2025: -$8.28 million | Fiscal year 2024: -$13.19 million | Fiscal year 2023: -$48.93 million | Fiscal year 2022: -$42.20 million | Fiscal year 2021: -$32.72 million | Fiscal year 2020: -$20.35 million | Fiscal year 2019: -$7.04 million | Fiscal year 2018: -$9.45 million | Fiscal year 2017: -$14.89 million | Fiscal year 2016: -$17.00 million | Fiscal year 2015: -$14.35 million | Fiscal year 2014: -$5.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: